Novavax, the leading biotechnology firm, and Moderna have reportedly entered into a new deal with the government of South Korea to manufacture coronavirus vaccines. The country has been under a lot of pressure to secure more and also speed up deliveries of the United States-made vaccines.
The deals with the U.S.-based drug makers came on Saturday, just a day after Joe Biden, the President of the Unites States stated that he and the President of South Korea, Moon Jae-in, both had settled on a comprehensive partnership on coronavirus related vaccines and that the U.S. will also provide inoculations for approximately 550,000 soldiers in South Korea.
Moderna the leading biotechnology and pharmaceutical firm whose vaccine was given approval in the country, stated that the doses would be made by Samsung Biologics and that it also plans to supply vaccine doses to markets that are outside the U.S. starting in Q3.
Kang Do-tae, Vice-Minister of Health, stated that the country emerged as a worldwide vaccine production base with its 4th coronavirus vaccine contract manufacturing agreement.
The country has deals to produce coronavirus vaccines locally from Sputnik V of Russia, Novavax and Oxford-AstraZeneca. South Korea has in fact gained access to approximately 40 million doses of COVID-19 vaccines of Moderna as per the authorities.
Novavax has also confirmed its partnership with SK Bioscience, a leading firm in South Korea to expand its vaccines production, which includes the United States drug developer's protein-related coronavirus vaccine candidate.
Novavax, in February, had entered into a new license agreement with SK Bioscience to produce nearly 40 million COVID-19 vaccine doses for South Korea.
The country, which has inoculated less than 10% of its overall 52 million people, aims to jab at least 70% by September.
South Korea has ordered as many as 192 million vaccine doses from Johnson & Johnson, Moderna, Novavax, AstraZeneca, and Pfizer-BioNTech.
The country reported around 585 new coronavirus cases on Saturday, totaling up to 135,929, with approximately 1,931 deaths.